Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Rigel Pharmaceuticals's enterprise value is €537.8 Mil.
Rigel Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was €113.0 Mil. Therefore, Rigel Pharmaceuticals's EV-to-EBITDA for today is 4.76.
The historical rank and industry rank for Rigel Pharmaceuticals's EV-to-EBITDA or its related term are showing as below:
FRA:RI2'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -213.47 Med: -4.54 Max: 35.58
Current: 4.66
During the past 13 years, the highest EV-to-EBITDA of Rigel Pharmaceuticals was 35.58. The lowest was -213.47. And the median was -4.54.
FRA:RI2's EV-to-EBITDA is ranked better than 64.86% of 407
companies
in the Biotechnology industry
Industry Median: 11.7
vs FRA:RI2: 4.66
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Rigel Pharmaceuticals's PE Ratio (TTM) for today is calculated as:
Rigel Pharmaceuticals's share price for today is €32.56.
Rigel Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €16.032.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
Rigel Pharmaceuticals EV-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Rigel Pharmaceuticals's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:RI2 vs SGP, OCS, GYRE: EV-to-EBITDA Comparison
For the Biotechnology subindustry, Rigel Pharmaceuticals's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Rigel Pharmaceuticals EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Rigel Pharmaceuticals's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Rigel Pharmaceuticals's EV-to-EBITDA falls into.
Rigel Pharmaceuticals's current Enterprise Value is €537.8 Mil.
Rigel Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €113.0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Rigel Pharmaceuticals (FRA:RI2) has a EV-to-EBITDA of 4.76 as of Jul. 29, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Rigel Pharmaceuticals. According to the industry distribution chart, Rigel Pharmaceuticals ranks #143 out of 407 companies in the Biotechnology industry, placing it in the top 35.1%.
Is Rigel Pharmaceuticals' EV-to-EBITDA too high?
Rigel Pharmaceuticals' current EV-to-EBITDA is 4.76. The Biotechnology industry median EV-to-EBITDA is 11.70. Rigel Pharmaceuticals' value of 4.76 is 59.3% below this industry median. Based on the distribution chart, Rigel Pharmaceuticals ranks #143 out of 407 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Rigel Pharmaceuticals has a GF Score™ of 24/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Rigel Pharmaceuticals' EV-to-EBITDA compare to SGP and OCS?
According to the Biotechnology industry distribution chart, Rigel Pharmaceuticals ranks #143 out of 407 companies for EV-to-EBITDA. This puts Rigel Pharmaceuticals in the upper half of its industry. The industry median EV-to-EBITDA is 11.70. Rigel Pharmaceuticals' value of 4.76 is 59.3% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 11.70, based on 407 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Rigel Pharmaceuticals's current EV-to-EBITDA of 4.76 is 59.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Rigel Pharmaceuticals. For the Biotechnology industry, the median EV-to-EBITDA is 11.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Rigel Pharmaceuticals's current EV-to-EBITDA is 4.76. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rigel Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Rigel Pharmaceuticals (FRA:RI2) is currently considered Significantly Overvalued. The stock's GF Value™ is €23.54, compared to a current price of €32.56 — trading 38.3% above its estimated fair value. The current EV-to-EBITDA is 4.76 and 59.3% below the Biotechnology industry median of 11.70. Rigel Pharmaceuticals' overall GF Score™ is 24/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Rigel Pharmaceuticals (FRA:RI2), the current EV-to-EBITDA is 4.76 as of Jul. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Rigel Pharmaceuticals (FRA:RI2) Overvalued in 2026?
Based on GuruFocus' analysis, Rigel Pharmaceuticals stock appears to be overvalued.
The current stock price of €32.56 is trading 38.3% above its estimated GF Value™ of €23.54.
GuruFocus considers Rigel Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for FRA:RI2:
EV-to-EBITDA: 4.76
GF Value™: €23.54 vs. price of €32.56 (38.3% above fair value)
Industry Position: 59.3% below the Biotechnology median (#143 of 407)
No single metric tells the full story. See the FRA:RI2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.
24GF Score
Get the complete analysis for FRA:RI2
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:RI2 has been successfully added to your 
